Werewolf Therapeutics reported Q3 2025 results with continued investment in R&D for its lead INDUKINE programs, WTX-124 and WTX-330, and the INDUCER T-cell engager candidate, WTX-1011. The company expects significant clinical updates in Q4 2025, including interim data for WTX-124 and development plans for WTX-330, while maintaining a cash runway into Q4 2026.
Cash and cash equivalents of $65.7 million are sufficient to fund operational expenses and capital expenditure requirements into the fourth quarter of 2026.
positiveFast Track Designation received from the US FDA for WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma.
positiveEnrollment is expected to be completed in all arms of the WTX-124 Phase 1/1b clinical trial by the first quarter of 2026.
neutralInterim data from WTX-124 and feedback from the End of Phase 1 meeting with the FDA are expected in Q4 2025.
neutralUpdate on WTX-330 clinical trial and potential development plan expected in Q4 2025.
neutralProgress in IND-enabling studies for WTX-1011, with nomination of a differentiated target candidate expected by year-end.
neutralRevenue was $0 for the third quarter of 2025, consistent with the prior year, indicating no commercial product sales.
negativeNet loss was $16.4 million for the third quarter of 2025, a slight improvement from $16.7 million in the prior year, but still reflects significant ongoing operational costs.
attentionCash and cash equivalents decreased from $77.6 million as of June 30, 2025, to $65.7 million as of September 30, 2025, indicating burn rate.
attentionResearch and development expenses were $11.6 million for Q3 2025, slightly down from $12.5 million in Q3 2024, but still a significant expenditure without current revenue.
attentionMargin metrics will be available once backend extracts data from insights_json
Werewolf is delivering on the promise of its proprietary PREDATOR® platform of conditionally activated immune therapeutics.
Significant progress for lead INDUKINETM clinical programs, WTX-124 and WTX-330, and the first INDUCER T-cell engager candidate, WTX-1011.
Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the FDA expected later in Q4 2025.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.